Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 2:44 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 64 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Standard Dose of Unfractionated Heparin Clear all

Conditions: Deep Vein Thrombosis, Pulmonary Embolism, Venous Thromboembolism
Interventions: Standard heparin dose, Real time heparin dose adjustment; Drug
Lead sponsor: University of Utah; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Sars-CoV2, COVID
Interventions: Enoxaparin, Prophylactic/Intermediate Dose Enoxaparin; Drug
Lead sponsor: Northwell Health; Other
Eligibility: 18 Years and older
Enrollment: 257 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 6
States / cities: Newark, New Jersey • Bay Shore, New York • Huntington, New York + 3 more

Conditions: Multiple Myeloma
Interventions: Epoetin Alfa, Exercise, Autologous Peripheral Blood Stem Cell Transplantation, Red Blood Cell Transfusion, Thalidomide, Heparin, Low-Molecular-Weight, Platelet Transfusion, Melphalan, Total Therapy II; Drug · Behavioral · Biological
Lead sponsor: University of Arkansas; Other
Eligibility: Not listed
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2004
U.S. locations: 1
States / cities: Little Rock, Arkansas

Conditions: Coagulation; Intravascular
Interventions: Protamine fixed dose, Protamine ratio dose; Drug
Lead sponsor: University of Miami; Other
Eligibility: 18 Years and older
Enrollment: 130 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 2
States / cities: Miami, Florida

Conditions: Pulmonary Embolism, Thrombotic Disease
Interventions: DS-1040b, Placebo, Enoxaparin; Drug
Lead sponsor: Daiichi Sankyo; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 134 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 15
States / cities: Mobile, Alabama • Beverly Hills, California • San Diego, California + 12 more

Conditions: Acute Coronary Syndrome (ACS)
Interventions: REG1, Heparin; Drug
Lead sponsor: Regado Biosciences, Inc.; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 640 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 26
States / cities: Huntsville, Alabama • Sacramento, California • San Diego, California + 21 more

Conditions: Covid19
Interventions: theraputic heparin, prophylactic heparin, P2Y12, Crizanlizumab Injection, SGLT2 inhibitor; Drug
Lead sponsor: Matthew Neal MD; Other
Eligibility: 18 Years and older
Enrollment: 3,591 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 81
States / cities: Birmingham, Alabama • Tucson, Arizona • Little Rock, Arkansas + 65 more

Conditions: Cardiovascular Diseases, Bleeding, Arterial Puncture, Catheter Complications, Occlusion of Artery
Interventions: Heparin, Terumo Radial Band, Vaosband; Drug · Device
Lead sponsor: Regional Hospital of Scranton; Other
Eligibility: 18 Years and older
Enrollment: 451 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Scranton, Pennsylvania

Conditions: Venous Thromboembolism, Thromboprophylaxis, Trauma
Interventions: Aspirin, Enoxaparin; Drug
Lead sponsor: University of Miami; Other
Eligibility: 18 Years and older
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Covid19
Interventions: rNAPc2, Heparin; Drug
Lead sponsor: ARCA Biopharma, Inc.; Industry
Eligibility: 18 Years to 90 Years
Enrollment: 160 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 11
States / cities: Fairhope, Alabama • Phoenix, Arizona • Tucson, Arizona + 8 more

Conditions: Multiple Myeloma
Interventions: Siltuximab, Melphalan; Drug
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 60 Years and older
Enrollment: 215 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 7
States / cities: Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more

Conditions: Venous Thromboembolism
Interventions: Enoxaparin; Drug
Lead sponsor: Hamilton Health Sciences Corporation; Other
Eligibility: Up to 18 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2022
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Thromboembolic Complications
Interventions: Enoxaparin dose adjusted Lovenox based on TEG, Enoxaparin 30 mg BID; Drug
Lead sponsor: Oregon Health and Science University; Other
Eligibility: 15 Years and older
Enrollment: 185 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2015
U.S. locations: 3
States / cities: Portland, Oregon • Houston, Texas • Seattle, Washington

Conditions: Venous Thrombosis
Interventions: low dose intravenous heparin (LDIVH), Heparin; Drug
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 18 Years to 80 Years
Enrollment: 152 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2014
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Pulmonary Embolism, COVID
Interventions: TNKase, Placebo, Enoxaparin; Drug
Lead sponsor: Cedars-Sinai Medical Center; Other
Eligibility: 18 Years to 75 Years
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Small Cell Lung Cancer
Interventions: Etoposide, Cisplatin, enoxaparin sodium; Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2008
U.S. locations: 4
States / cities: Boston, Massachusetts • Peabody, Massachusetts

Conditions: Acute Respiratory Failure, Extracorporeal Membrane Oxygenation Complication, Bleeding
Interventions: HEP-IV; Drug
Lead sponsor: University of Arizona; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2021
U.S. locations: 1
States / cities: Phoenix, Arizona

Conditions: Venous Thrombosis, Neoplasms
Interventions: Heparin, Low-Molecular-Weight, or direct oral anticoagulants; Drug
Lead sponsor: Medical College of Wisconsin; Other
Eligibility: 18 Years and older
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2022
U.S. locations: 3
States / cities: Minneapolis, Minnesota • Columbus, Ohio • Milwaukee, Wisconsin

Conditions: Obesity
Interventions: Enoxaparin; Drug
Lead sponsor: Emory University; Other
Eligibility: 18 Years and older
Enrollment: 62 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Postoperative Hemorrhage
Interventions: Heparin, HH or high heparin, heparin concentration HC; Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years to 90 Years
Enrollment: 270 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2007
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Acute Kidney Injury, Acute Renal Failure, Heart Failure
Interventions: Dilute unfractionated heparin, Standard concentration unfractionated heparin; Drug
Lead sponsor: Vanderbilt University; Other
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2016
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Lymphoma
Interventions: Lenalidomide, Vorinostat, Gemcitabine, Busulfan, Melphalan, Rituximab, Dexamethasone, Caphosol, Glutamine, Pyridoxine, Enoxaparin, Stem Cell Transplant, Palifermin; Drug · Procedure
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 15 Years to 65 Years
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Acute Myeloid Leukemia
Interventions: Dociparstat sodium, Idarubicin, Cytarabine; Drug
Lead sponsor: Jazz Pharmaceuticals; Industry
Eligibility: 60 Years and older
Enrollment: 75 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 23
States / cities: La Jolla, California • Denver, Colorado • Washington D.C., District of Columbia + 19 more

Conditions: Heart Disease
Interventions: Rb-82 Pet scans, F-18 FDG Pet scans, N-13 ammonia Pet scans, Regadenoson; Other · Drug
Lead sponsor: University of Michigan; Other
Eligibility: 30 Years to 70 Years
Enrollment: 70 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2018
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Search by objective public record fields.

Evaluation of Anti-Xa Levels in Surgery Patients Receiving Weight-based Heparin

Full Dose Heparin Vs. Prophylactic Or Intermediate Dose Heparin in High Risk COVID-19 Patients

Effects of Exercise in Combination With Epoetin Alfa

Optimal Protamine Dosing for Heparin Reversal Following Cardiopulmonary Bypass

Study to Assess the Safety, Pharmacokinetics/Dynamics of DS-1040b in Subjects With Acute Submassive Pulmonary Embolism

A Study Assessing the REG1 Anticoagulation System Compared Heparin in Subjects With Acute Coronary Syndrome

Accelerating COVID-19 Therapeutic Interventions and Vaccines 4 ACUTE

Safe and Fast Radial Hemostasis Using Synergistic Strategies: SAFE & FAST Trial

Aspirin and Enoxaparin for VTE in Trauma

Assessing Safety, Hospitalization and Efficacy of rNAPc2 in COVID-19

A Study of Melphalan With or Without Siltuximab in People With Multiple Myeloma Having an Autologous Stem Cell Transplant

Pilot Feasibility and Safety of Administering Weight Adjusted Fixed LMWH Dose

Thrombelastography Based Dosing of Enoxaparin

Using Intravenous Heparin Versus Standard of Care Subcutaneous Heparin to Prevent Clots After Surgery

Low-Dose Tenecteplase in Covid-19 Diagnosed With Pulmonary Embolism

A Randomized Study to Evaluate the Effect of Two Different Doses of Enoxaparin Sodium in Combination With Standard Chemotherapy in Patients With Stage Small Cell Lung Cancer (SCLC)

Fixed Low-dose Heparin Versus Standard Adjusted-dose Heparin Infusion in Adults Receiving Venovenous ECMO With a Heparin Bonded Circuit.

Post-thrombotic Syndrome & Predictors of Recurrence in Catheter-related Thrombosis

Enoxaparin Dosing in Obesity

Optimal Heparin Dosing Regimens for Cardiopulmonary Bypass

A Comparison of Dilute Versus Concentrated Heparin for CRRT Anticoagulation

Lenalidomide Combined With Vorinostat/Gemcitabine/Busulfan/Melphalan With Autologous Stem-Cell Transplantation in Diffuse Large B-Cell Lymphoma of the ABC Subtype

Dociparstat Sodium (CX-01) Combined With Standard Induction Therapy for Newly Diagnosed Acute Myeloid Leukemia

Distribution of Rubidium-82, Nitrogen-13 Ammonia, and Fluorine-18 Fluorodeoxyglucose in Normal Volunteers